v3.26.1
Description of Organization and Business Operations (Details Narrative)
1 Months Ended 12 Months Ended
Oct. 01, 2025
$ / shares
shares
Aug. 22, 2025
shares
Jun. 24, 2025
USD ($)
$ / shares
Apr. 11, 2025
USD ($)
$ / shares
shares
Jul. 25, 2024
shares
Sep. 13, 2023
USD ($)
$ / shares
shares
May 30, 2025
shares
Mar. 29, 2025
shares
Jul. 31, 2024
$ / shares
shares
Apr. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Jul. 31, 2024
$ / shares
shares
Jan. 16, 2026
USD ($)
Oct. 02, 2025
$ / shares
Jul. 31, 2025
$ / shares
shares
Jul. 31, 2025
RM / shares
shares
May 13, 2025
$ / shares
Aug. 19, 2024
shares
Jul. 31, 2024
RM / shares
shares
Jan. 08, 2024
$ / shares
Jul. 31, 2023
shares
Aug. 19, 2019
Common stock shares outstanding                 1         1     1 1     1      
Common stock, par value | $ / shares                 $ 0.001         $ 0.001     $ 0.001              
Subsequent Event [Member]                                                
Common stock, par value | $ / shares $ 0.0001                                              
Common Stock [Member]                                                
Stock Issued During Period, Shares, New Issues                 1                              
Titan Pharmaceuticals Inc [Member]                                                
Shares issued | $ / shares                         $ 0.001                      
Settlement expenses | $                   $ 1,200,000                            
Common stock shares outstanding                       1,000 914,234                      
Common stock, par value | $ / shares                       $ 0.001 $ 0.001     $ 0.0001           $ 0.001    
Cash, FDIC insured amount | $                       $ 250,000                        
Rent expense | $                       $ 0 $ 64,000                      
Titan Pharmaceuticals Inc [Member] | Computer Equipment [Member]                                                
Property and equipment estimated useful lives                       3 years                        
Titan Pharmaceuticals Inc [Member] | Chairman of the Board and Chief Executive Officer [Member] | Talen Tec [Member]                                                
Ownership interest by Activist                                               47.40%
Titan Pharmaceuticals Inc [Member] | Series C Preferred Stock [Member] | Blue Harbour Asset Management LLC [Member]                                                
Shares issued | $ / shares     $ 10.00                                          
Titan Pharmaceuticals Inc [Member] | Series A Preferred Stock [Member]                                                
Merger related transaction | $                       $ 5,500,000                        
TALENTEC SDN. BHD. [Member]                                                
Common stock shares outstanding                 580,000         580,000             580,000   500,000  
Common stock, par value | (per share)                 $ 0.36         $ 0.36     $ 0.36 RM 1     RM 1      
Share Price | $ / shares $ 8.524                                              
Stock Issued During Period, Shares, New Issues 7,210,800       80,000                                      
TALENTEC SDN. BHD. [Member] | Keda Pte Ltd [Member]                                                
Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage                                 100.00% 100.00%            
TALENTEC SDN. BHD. [Member] | Common Stock [Member]                                                
Stock Issued During Period, Shares, New Issues                           80,000                    
Securities Purchase Agreement [Member] | Titan Pharmaceuticals Inc [Member] | Subsequent Event [Member]                                                
Debt financing facility | $                             $ 200,000,000                  
Principal amount | $                             $ 1,515,000                  
Fedson, Inc. [Member] | Sire Purchase Agreement [Member] | Titan Pharmaceuticals Inc [Member]                                                
Sale of assets | $                     $ 2,000,000.0                          
Sire Group Ltd [Member] | Titan Pharmaceuticals Inc [Member]                                                
Shares issued             150,087                                  
Sire Group Ltd [Member] | Titan Pharmaceuticals Inc [Member] | Series AA Preferred Stock [Member]                                                
Shares issued | $ / shares                                     $ 0.001          
Sire Group Ltd [Member] | Sire Purchase Agreement [Member] | Titan Pharmaceuticals Inc [Member]                                                
Shares issued           950,000                                    
Reverse stock split           1-for-20                                    
Sire Group Ltd [Member] | Sire Purchase Agreement [Member] | Titan Pharmaceuticals Inc [Member] | Series AA Preferred Stock [Member]                                                
Shares issued | $ / shares           $ 10.00                                    
Agreegate purchase price | $           $ 9,500,000                                    
Conversion price | $ / shares           $ 9.32                                    
Blue Harbour [Member] | Titan Pharmaceuticals Inc [Member]                                                
Shares issued   67,420         265,913                                  
Blue Harbour [Member] | Titan Pharmaceuticals Inc [Member] | Series B Preferred Stock [Member]                                                
Shares issued               100,000                                
Shares issued | $ / shares                                     $ 0.001          
Blue Harbour [Member] | Titan Pharmaceuticals Inc [Member] | Series B Preferred Stock [Member] | Blue Harbour Asset Management LLC [Member]                                                
Shares issued       100,000                                        
Shares issued | $ / shares       $ 10.00                                        
Agreegate purchase price | $     $ 60,000 $ 1,000,000                                        
Blue Harbour [Member] | Titan Pharmaceuticals Inc [Member] | Series C Preferred Stock [Member] | Blue Harbour Asset Management LLC [Member]                                                
Agreegate purchase price | $     $ 600,000                                          
TTNP Merger Sub, Inc. [Member] | Titan Pharmaceuticals Inc [Member] | Common Stock [Member]                                                
Common stock shares outstanding                                       1,000